ADC Therapeutics (ADCT) Accounts Payables (2019 - 2026)
ADC Therapeutics (ADCT) posted Accounts Payables of $5.3 million for Q1 2026, down 42.29% sequentially from $9.2 million in Q4 2025, and down 66.04% YoY from $15.6 million in Q1 2025.
ADC Therapeutics (ADCT) Accounts Payables (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Accounts Payables for 8 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Accounts Payables fell 66.04% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 66.04% YoY) and the FY2025 annual result came in at $9.2 million, down 49.11% from the prior year.
- Accounts Payables fell to $5.3 million in Q1 2026 per ADCT's latest filing, from $9.2 million in the prior quarter.
- Over five years, Accounts Payables peaked at $18.0 million in Q4 2024 and troughed at $5.3 million in Q1 2026.
- A 5-year average of $12.0 million and a median of $11.7 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2026: Accounts Payables surged 64.65% in 2024, then slumped 66.04% in 2026.
- Over 5 years, Accounts Payables stood at $12.4 million in 2022, then climbed by 26.05% to $15.6 million in 2023, then rose by 15.8% to $18.0 million in 2024, then tumbled by 49.11% to $9.2 million in 2025, then plunged by 42.29% to $5.3 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $5.3 million, $9.2 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | 12.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.76 Mn |
| Mar 31, 2026 | 5.30 Mn |
| Dec 31, 2025 | 9.18 Mn |
| Sep 30, 2025 | 8.12 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Mar 31, 2025 | 15.59 Mn |
| Dec 31, 2024 | 18.03 Mn |
| Sep 30, 2024 | 14.37 Mn |
| Jun 30, 2024 | 10.71 Mn |
| Mar 31, 2024 | 14.32 Mn |
| Dec 31, 2023 | 15.57 Mn |
| Sep 30, 2023 | 8.98 Mn |
| Jun 30, 2023 | 11.69 Mn |
| Mar 31, 2023 | 8.69 Mn |
| Dec 31, 2022 | 12.35 Mn |
| Sep 30, 2022 | 11.61 Mn |
| Jun 30, 2022 | 13.02 Mn |
| Mar 31, 2022 | 16.45 Mn |
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 12.03 Mn |